Cantor analyst Mara Goldstein raised her price target on NewLink, citing her "increased conviction about" its indoximod drug "and overall IDO program." The analyst thinks that the market is misinterpreting data presented on indoximod at AACR. Specifically, she says that the drug's 12% complete response rate validates it, given its 52% overall response rate and 73% disease control rate. She adds that the drug has better tolerability than the CTLA-4 and PD-L1 inhibitor combination., The analyst believes that this discrepancy could give indoximod "a significant advantage." Goldstein raised her price target on the stock to $32 from $20 and keeps a Buy rating.